Towards an Evidence-based Taxonomy of Nonpharmacologic Treatments for ADHD

Stephen V. Faraone; Kevin M. Antshel

doi:10.1016/j.chc.2014.06.003

Towards an Evidence-based Taxonomy of Nonpharmacologic Treatments for ADHD

Stephen V. Faraone, Kevin M. Antshel

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

We have created an evidence-based guide for clinicians to the relative utility of nonpharmacologic treatments for attention-deficit/hyperactivity disorder (ADHD). This article uses the term evidence-based in the sense applied by the Oxford Center for Evidenced-Based Medicine to help readers understand the degree to which nonpharmacologic treatments are supported by the scientific literature. This article also reviews the magnitude of the treatment effect expressed as the standardized mean difference effect size (also known as Cohen D). It then describes a meta-algorithm to describe how to integrate pharmacologic and nonpharmacologic treatments for ADHD.

Original language	English (US)
Pages (from-to)	965-972
Number of pages	8
Journal	Child and Adolescent Psychiatric Clinics of North America
Volume	23
Issue number	4
DOIs	https://doi.org/10.1016/j.chc.2014.06.003
State	Published - 2014
Externally published	Yes

Keywords

ADHD
Alternative treatments
Children
Medications
Psychosocial
Therapy
Treatment

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Psychiatry and Mental health

Access to Document

10.1016/j.chc.2014.06.003

Cite this

@article{551145b2b7e64c7ba4a39cc17299e4c3,

title = "Towards an Evidence-based Taxonomy of Nonpharmacologic Treatments for ADHD",

abstract = "We have created an evidence-based guide for clinicians to the relative utility of nonpharmacologic treatments for attention-deficit/hyperactivity disorder (ADHD). This article uses the term evidence-based in the sense applied by the Oxford Center for Evidenced-Based Medicine to help readers understand the degree to which nonpharmacologic treatments are supported by the scientific literature. This article also reviews the magnitude of the treatment effect expressed as the standardized mean difference effect size (also known as Cohen D). It then describes a meta-algorithm to describe how to integrate pharmacologic and nonpharmacologic treatments for ADHD.",

keywords = "ADHD, Alternative treatments, Children, Medications, Psychosocial, Therapy, Treatment",

author = "Faraone, {Stephen V.} and Antshel, {Kevin M.}",

note = "Funding Information: In the past year, Dr S.V. Faraone received consulting income, travel expenses, and/or research support from Ironshore , Shire , Akili Interactive Labs , Alcobra , VAYA , and Neurovance ; and research support from the National Institutes of Health (NIH). His institution is seeking a patent for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on advisory boards or participated in continuing medical education programs sponsored by: Shire, Alcobra, Otsuka , McNeil , Janssen , Novartis , Pfizer , and Eli Lilly . Dr S.V. Faraone receives royalties from books published by Guilford Press (Straight Talk about Your Child{\textquoteright}s Mental Health) and Oxford University Press (Schizophrenia: The Facts). Publisher Copyright: {\textcopyright} 2014 Elsevier Inc.",

year = "2014",

doi = "10.1016/j.chc.2014.06.003",

language = "English (US)",

volume = "23",

pages = "965--972",

journal = "Child and Adolescent Psychiatric Clinics of North America",

issn = "1056-4993",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Towards an Evidence-based Taxonomy of Nonpharmacologic Treatments for ADHD

AU - Faraone, Stephen V.

AU - Antshel, Kevin M.

N1 - Funding Information: In the past year, Dr S.V. Faraone received consulting income, travel expenses, and/or research support from Ironshore , Shire , Akili Interactive Labs , Alcobra , VAYA , and Neurovance ; and research support from the National Institutes of Health (NIH). His institution is seeking a patent for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on advisory boards or participated in continuing medical education programs sponsored by: Shire, Alcobra, Otsuka , McNeil , Janssen , Novartis , Pfizer , and Eli Lilly . Dr S.V. Faraone receives royalties from books published by Guilford Press (Straight Talk about Your Child’s Mental Health) and Oxford University Press (Schizophrenia: The Facts). Publisher Copyright: © 2014 Elsevier Inc.

PY - 2014

Y1 - 2014

N2 - We have created an evidence-based guide for clinicians to the relative utility of nonpharmacologic treatments for attention-deficit/hyperactivity disorder (ADHD). This article uses the term evidence-based in the sense applied by the Oxford Center for Evidenced-Based Medicine to help readers understand the degree to which nonpharmacologic treatments are supported by the scientific literature. This article also reviews the magnitude of the treatment effect expressed as the standardized mean difference effect size (also known as Cohen D). It then describes a meta-algorithm to describe how to integrate pharmacologic and nonpharmacologic treatments for ADHD.

AB - We have created an evidence-based guide for clinicians to the relative utility of nonpharmacologic treatments for attention-deficit/hyperactivity disorder (ADHD). This article uses the term evidence-based in the sense applied by the Oxford Center for Evidenced-Based Medicine to help readers understand the degree to which nonpharmacologic treatments are supported by the scientific literature. This article also reviews the magnitude of the treatment effect expressed as the standardized mean difference effect size (also known as Cohen D). It then describes a meta-algorithm to describe how to integrate pharmacologic and nonpharmacologic treatments for ADHD.

KW - ADHD

KW - Alternative treatments

KW - Children

KW - Medications

KW - Psychosocial

KW - Therapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84922539421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922539421&partnerID=8YFLogxK

U2 - 10.1016/j.chc.2014.06.003

DO - 10.1016/j.chc.2014.06.003

M3 - Review article

C2 - 25220096

AN - SCOPUS:84922539421

SN - 1056-4993

VL - 23

SP - 965

EP - 972

JO - Child and Adolescent Psychiatric Clinics of North America

JF - Child and Adolescent Psychiatric Clinics of North America

IS - 4

ER -

Towards an Evidence-based Taxonomy of Nonpharmacologic Treatments for ADHD

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this